|
|
Article: Research from Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins provides new data about leukemia therapy.(Report)
- Article from:
- Blood Weekly
- Article date:
- November 6, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New research, 'Targeting FLT3 for the Treatment of Leukemia,' is the subject of a report. According to recent research from the United States, "FLT3 is a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell survival and proliferation. It is frequently overexpressed in acute leukemias and is frequently mutated in acute myeloid leukemia (AML)."
"FLT3 internal tandem duplication (ITD) mutations in AML portend poor prognosis in both adult and pediatric patients. A number of small molecule tyrosine kinase inhibitors (TKIs) with activity against FLT3 have been discovered. Many of these are still in preclinical development, but several ...
Related newspaper, magazine, and journal articles:
|
|
Article: Research conducted at Johns Hopkins University, ...
Cancer Weekly;
December 23, 2008 ;
700+ words
... ... cells," wrote T.J. Webb and colleagues, Johns Hopkins University, Sidney Kimmel Cancer Center. The researchers concluded ... Comprehensive Cancer Center, Dept. of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205 ...
|
|